TLR4 as a negative regulator of keratinocyte proliferation by Iotzova-Weiss, Guergana et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
TLR4 as a negative regulator of keratinocyte proliferation
Iotzova-Weiss, Guergana; Freiberger, Sandra N; Johansen, Pål; Kamarachev, Jivko; Guenova,
Emmanuella; Dziunycz, Piotr J; Roux, Guillaume A; Neu, Johannes; Hofbauer, Günther F L
Abstract: TLR4 is an innate immune receptor with expression in human skin, keratinocytes as well as
squamous cell carcinoma (SCC) of the skin. In the present study we investigate the role of TLR4 as a
negative regulator of keratinocyte proliferation. We present here that the expression of TLR4 increased
with the differentiation of cultured keratinocytes in a passage-dependent manner or under calcium-rich
conditions. Moreover, the down-regulation of TLR4 by specific knockdown increased the proliferation of
HaCaT keratinocytes in vitro. In addition, subcutaneously injected HaCaT keratinocytes with shTLR4
formed growing tumors in nude mice. In contrast, we observed lower proliferation and increased migration
in vitro of the SCC13 cell line stably overexpressing TLR4 in comparison to SCC13 TLR4 negative cells.
In vivo, SCC13 TLR4-overexpressing tumors showed delayed growth in comparison to TLR4 negative
tumors. The overexpression of TLR4 in SCC13 tumor cells was followed by phosphorylation of ERK1/2
and JNK and increased expression of ATF3. In gene expression arrays, the overexpression of TLR4 in
tumor cells correlated with gene expression of ATF-3, IL-6, CDH13, CXCL-1 and TFPI. In summary,
TLR4 negatively regulates the proliferation of keratinocytes and its overexpression reduces tumor growth
of SCC cells.
DOI: https://doi.org/10.1371/journal.pone.0185668
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-143352
Veröffentlichte Version
 
 
Originally published at:
Iotzova-Weiss, Guergana; Freiberger, Sandra N; Johansen, Pål; Kamarachev, Jivko; Guenova, Em-
manuella; Dziunycz, Piotr J; Roux, Guillaume A; Neu, Johannes; Hofbauer, Günther F L (2017). TLR4
as a negative regulator of keratinocyte proliferation. PLoS ONE, 12(10):e0185668.
DOI: https://doi.org/10.1371/journal.pone.0185668
RESEARCH ARTICLE
TLR4 as a negative regulator of keratinocyte
proliferation
Guergana Iotzova-Weiss*, Sandra N. Freiberger, Pål Johansen, Jivko Kamarachev,
Emmanuella Guenova, Piotr J. Dziunycz, Guillaume A. Roux, Johannes Neu, Gu¨nther F.
L. Hofbauer
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
* geri.weiss@web.de
Abstract
TLR4 is an innate immune receptor with expression in human skin, keratinocytes as well as
squamous cell carcinoma (SCC) of the skin. In the present study we investigate the role of
TLR4 as a negative regulator of keratinocyte proliferation. We present here that the expres-
sion of TLR4 increased with the differentiation of cultured keratinocytes in a passage-depen-
dent manner or under calcium-rich conditions. Moreover, the down-regulation of TLR4 by
specific knockdown increased the proliferation of HaCaT keratinocytes in vitro. In addition,
subcutaneously injected HaCaT keratinocytes with shTLR4 formed growing tumors in nude
mice. In contrast, we observed lower proliferation and increased migration in vitro of the
SCC13 cell line stably overexpressing TLR4 in comparison to SCC13 TLR4 negative cells.
In vivo, SCC13 TLR4-overexpressing tumors showed delayed growth in comparison to
TLR4 negative tumors. The overexpression of TLR4 in SCC13 tumor cells was followed by
phosphorylation of ERK1/2 and JNK and increased expression of ATF3. In gene expression
arrays, the overexpression of TLR4 in tumor cells correlated with gene expression of ATF-3,
IL-6, CDH13, CXCL-1 and TFPI. In summary, TLR4 negatively regulates the proliferation of
keratinocytes and its overexpression reduces tumor growth of SCC cells.
Introduction
The keratinocyte cell cycle is determined by proliferation and terminal differentiation, two
processes that control and maintain the normal skin homeostasis. The basal skin layer is char-
acterized by highly proliferative keratinocytes, expressing the differentiation markers K5 and
K14. Well differentiated keratinocytes sustain the spinous, granular and corneal layers, have
decreased proliferation potential and are characterized by the expression of K1, K10, involu-
crin, loricrin, filaggrin [1]; [2, 3]. The signaling cascades regulating the process of keratinocyte
differentiation are dependent on the crosstalk between the different skin layers. Among the
signaling pathways involved in keratinocyte differentiation are Notch [4]; Wnt [5] and p63,
IRF6 [2, 6]. The dysregulation of these signaling pathways is observed in both inflammatory
skin diseases such as psoriasis and non-melanoma skin cancer, such as SCC [7]; [8]; [9]; [10].
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Toll like receptor 4 (TLR4) is a pattern recognition receptor and a key component of the
innate immune system. TLR4 is also expressed in skin and cultured keratinocytes [11]; [12].
Of relevance for keratinocyte biology, it is reported that the adaptor protein TRIP (TRAF-
interacting protein) regulates keratinocyte proliferation and differentiation [13]. The role of
TLR4 is investigated in skin diseases such as dermatitis and psoriasis [14]; SCC [15] and mela-
noma [16], as well as in skin wound healing [17]; [18]. TLR4 signaling is reported to promote
development of SCC in a MyD88-dependent manner and to be required for the recruitment of
inflammatory cells during the carcinogenesis [19]. The development of epithelial tumors is
also described through the interaction of TLR4 with HMGB-1 in the extracellular skin fluid
causing the activation of NF-κB in keratinocytes. Thus, TLR4 mediates between inflammation
and epithelial tumor development [20]. TLR4 is also reported to play a role in the prevention
of chemically induced carcinogenesis through the activation of T cells [21]. The role of TLR4
in supporting cell growth or inducing apoptotic signals is presented mostly through the activa-
tion of other cell populations. However, a relation between TLR4 expression on keratinocytes
and their proliferation has not been investigated by now. In the present study we propose a
novel role for TLR4 as a regulator of keratinocyte proliferation.
Materials and methods
The use of clinically indicated biopsy material for the study was approved by the Swiss ethics
committee, Canton of Zu¨rich, Switzerland. Participants provided verbal and written informed
consent, approved by the Swiss ethics committee. Healthy and SCC skin was obtained from
patients at plastic surgery following informed consent as approved by the ethical committee of
the Canton of Zu¨rich, Switzerland, and described previously [22]; [23]; [9]; [24].
Immunohistochemistry (IHC)
TLR4 expression was analyzed in formalin-fixed paraffin-embedded skin samples obtained
from the archives of the Dermatology Department of University Hospital Zurich (approval
and agreement by the patients is documented). The tissue microarrays were composed of
tumors from 63% male patients with a median age of 67 years. All tumors were from chroni-
cally sun-damaged skin, with the head the most frequent location in 56%. The expression was
tested in normal skin (23 punch biopsies) and in moderately and well differentiated SCC skin
derived from organ transplant recipients and immunocompetent patients (225 punch biop-
sies). The diagnosis and the classification of the SCC samples were performed by board-certi-
fied dermatopathologists by the criteria published by the WHO on tumors of the skin. The
evaluation was performed by arbitrary evaluation of three board-certified dermatologists as
well as one board-certified dermatopathologist, all co-authors of this manuscript. The staining
intensity analysis was based on three selected areas chosen for the tissue microarray for every
human tumor and on the whole tumor section for every single mouse tumor.
The staining was performed using anti-human TLR4 monoclonal mouse antibody (HTA
125, Abcam), anti human mouse ATF3 antibody (Santa Cruz Biotechnology) and anti IRF6
antibody (kindly provided by Prof. Paolo Dotto, Department of Biochemistry, University of
Lausanne, Lausanne, Switzerland; Cutaneous Biology Research Center, Massachusetts General
Hospital, Charlestown, MA, USA) following the manufacturers‘protocol. All antibodies were
used in a working dilution of 1:100. The negative and positive controls for the stainings were
perfomed using sections from human placenta. The optimized staining conditions were used
afterwards for the stainings of the normal skin sections as well of the TMA sections. The inten-
sity of the staining was analyzed by arbitrary evaluation including the whole sample section
and presented as arbitrary units respectively as weak, middle and strong staining The
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CXCL-1, Chemokine (C-X-C motif) ligand 1; ERK,
Extracellular-signal Regulated Kinases; JNK, cJUN-
N-terminal kinase; MyD88, Myeloid differentiation
primary response 88; SCC, Squamous Cell
Carcinoma; TFPI, Tissue factor pathway inhibitor;
TLR4, Toll-like receptor 4.
expression level (intensity) of TLR4, IRF6, ATF3 and the IRF6/TLR4 and ATF3/TLR4 correla-
tion were evaluated using t-test and Anova. P-values below 0.0001 and 0.05 (p<0.05;
p<0.0001) were considered as significant.
Cell lines
The HaCaT cell line was obtained from Prof. Petra Boukamp, DKFZ, Heidelberg, Germany.
The SCC13 cell line (epidermal malignant Squamous Cell Carcinoma cell line) is an immortal-
ized cell line described by [25] and lacks expression of TLR4. For our experimental work it was
kindly provided by Prof. Paolo Dotto, Department of Biochemistry, University of Lausanne,
Lausanne, Switzerland; Cutaneous Biology Research Center, Massachusetts General Hospital,
Charlestown, MA, USA.
Both HaCaT and SCC13 cell lines were grown in DMEM medium (Dulbeco‘s Modified
Eagle Medium; ThermoFisher Scientific) containing 10% FBS (ThermoFisher Scientific).
Generation of primary keratinocyte cultures derived from healthy
individuals and SCC patients
Primary normal and primary SCC-derived keratinocytes (SCC7) were generated in-house
from normal skin (abdominoplastic reconstructive surgery) and biopsies from patients’ SCC
samples. Single keratinocytes were isolated from 3–4 mm punch biopsies following the stan-
dard protocol for generation of primary keratinocyte cultures (CELLnTEC, Bern, Switzer-
land). For sufficient separation of the epidermis and dermis the punch biopsies were
incubated overnight at 4˚C in keratinocyte selection medium (Progenitor Cell Targeted (PCT)
epidermal keratinocyte medium CnT07, low Ca2+, (CELLnTEC) with Dispase II (Roche).
Afterwards the epidermal part of the skin was incubated in trypsin at room temperature for 30
min to insure efficient isolation of single keratinocytes. Freshly isolated cells were washed with
medium and then transferred into CnT07 selection medium for continuous incubation (37˚C,
5%CO2). The selection keratinocyte medium excludes a contamination with other skin cells
(fibroblasts, melanocytes). All keratinocyte cultures were characterized as keratinocytes using
the keratinocyte marker Keratin-14 (K14) as well as keratinocyte differentiation markers invo-
lucrin and filaggrin.
In contrast to the cell line SCC13, primary patient-derived SCC (SCC7) cells have a long
but limited life span in culture.
Immunoblotting
Differentiation of primary keratinocytes: Normal and SCC7 primary keratinocytes were
grown in 6 cm dishes in 50% and full confluence (96 hours growth) or under high Ca2+ condi-
tions (1.5mM CaCl2) in CnT07 keratinocyte medium (CELLnTEC, Bern, Switzerland). Cells
were grown in the presence of Ca2+ for 24h, 48h and 96h. As positive control cells grown in a
low Ca2+- medium for 96 hours was used where cells have reached full confluency and pas-
sage-driven differentiation. Cells were lysed in RIPA buffer (conventional protocol). The
lysates were collected and subjected to SDS-PAGE, followed by immunoblotting using specific
antibodies against human TLR4 (H-80, sc10741, 1:100 dilution), involucrin (sc-21748, 1:100
dilution), filaggrin (sc-66192, 1:100 dilution) and actin (sc-47778, 1:200 dilution), all from
Santa Cruz Biotechnology. Incubation with primary antibodies was performed at 4˚C, over-
night. Incubation with secondary rabbit anti-mouse IgG H&L HRP (ab6728) was performed at
room temperature for 1 hour. Proteins were detected by ECL on Hyperfilm (Amersham, GE
Healthcare).
TLR4 and keratinocyte proliferation
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LPS stimulation of SCC13 TLR4 overexpressing cells
SCC13 TLR4 overexpressing and SCC13 control cells were grown in 6 cm dishes in serum free
DMEM medium for 24 hours. Afterwards cells were stimulated with ultrapure LPS (10μg/ml,
Sigma) for different time intervals (0–60 min). Cells were lysed in RIPA buffer; the lysates
were collected after each time interval and subjected to SDS-PAGE, followed by immunoblot-
ting. The phosphorylated and non-phosphorylated form of ERK1/2 and JNK was detected by
using specific rabbit polyclonal antibodies (anti-pp42/44 (#9101), anti-p42/44 (#9102); anti-
rabbit HRP (#7074), all from Cell Signaling; anti-β-Actin (sc-47778, Santa Cruz Biotechnology,
anti-mouse HRP (ab6728, Abcam). The expression of MyD88 (ab2064, Abcam) and IRAK-1
(D51G7, #4504, Cell signaling) upon LPS stimulation was analyzed using the same protein
lysates. The secondary HRP-conjugated antibodies were used based on their species specificity
to the primary antibodies.
ELISA: Cells were grown in 24 well plates till they reach 60% density. The expression of
secreted IL-6 was analysed by ELISA (R&D Systems) before and after LPS stimulation at 6h
and 24 hours. As controls unstimulated TLR4+ and TLR4- cells were used.
Knockdown study
HaCaT keratinocytes were infected with lentiviral particles carrying specific shTLR4 consruct
(sc- 40260-v) or shCtrl lentiviral particles (sc-108080), following the protocol conditions
(Santa Cruz Biotechnology). Positive clones were selected by puromycine selection. The
growth of the selected sh TLR4 and control clones, further grown under puromycine selection,
was analyzed by BrdU proliferation assay.
RNA extraction and qPCR
RNA was extracted using the TRIzol reagent (Invitrogen, Basel, Switzerland) following the
protocol provided by the manufacturer. cDNA was synthesized from 1μg total RNA using a
Reverse Transcription system kit (Promega). Specific primers for human TLR4 (Microsynth,
Switzerland), (fwd 5‘ GCCCTGCGTGGAGGTGGTTC3‘; rev 5‘ TGAGAAGGGGAGGTTG
TCGGGG3‘) were used. PCRs were performed by ViiA7 ™ Real-Time PCR System (Life Tech-
nologies) using FastStart Universal SYBR green Mix (ROX) (Roche).
Overexpression study
SCC13 tumor cells were stably transfected with control (pUNO, Invivogen) and TLR4 express-
ing plasmid (pUNO-TLR4GFP, Invivogen) following the manufacturer’s protocol. For the
selection of positive clones the transfected cells were further grown in DMEM medium con-
taining blasticidine (10μg/ml) as a selection marker. The positive clones were visualized based
on their GFP signal by fluorescent microscopy and FACS analysis. The cellular population
with higher GFP signal, respectively higher TLR4 expression, were sorted using FACS sorter
(FACSAria III) and further used in the study.
Scratch assay
SCC13 TLR4+ and control cells were maintained under starving conditions (3% fetal calf
serum) and treated with Mytomycine C (10 μg/ml) Sigma Aldrich) for 2 hours prior to the
scratch assay. The scratch assay was performed on 100% confluent cells using a blue pipette tip
for generating a cross region in every well. The number of migrated cells across the marked
region was counted 15 hours after the scratch and presented as percent of control. The time
TLR4 and keratinocyte proliferation
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point was chosen based on pilot experiments performed beforehand with several time-points
where 15 hours was shown to discriminate most before cell death sets in.
BrdU proliferation assay
Cells were seeded in 96 well plates in serum-free CnT07 or Dulbecco’s Modified Eagle
Medium, DMEM in a cell density of 4x103/well. Cell proliferation was measured using BrdU
proliferation assay (Millipore) according to the manufacturer’s instruction. The analysis of cell
proliferation was performed 24 hours after seeding. The percentage of cell proliferation was
calculated using the equation (mean OD of treated cells/mean OD of control cells) X 100.
Gene expression array
SCC13 TLR4 and SCC13 pUNO (control) cells were seeded in tetraplicates and treated with
10μg/ml ultrapure LPS for 24 hours. As controls untreated SCC13TLR4 and SCC13 pUNO
cells were used. RNA was extracted by the TRIzol method and cDNA was generated by reverse
transcription. The SurePrint G3 Human Gene Expression 8x60K (Agilent) with 50599 biologi-
cal features was used to analyze the samples. Gene expression comparison was performed
between untreated SCC13-TLR4 and control cells as well as between the LPS treated
SCC13-TLR4 and control cells. Differentially expressed genes were selected to be relevant if
the absolute log-fold change was more than 2 and significant when FDR adjusted p-value was
less than 0.05 (NCBI, GEO Number: GSE89856). The gene expression was validated by PCR.
Mice
The in vivo growth of HaCaT and SCC13 cell lines was analyzed in athymic nude mice (Hsd:
Athymic Nude-Fox1nu/Foxn1+, Harlan).
Ethics statement. Mice were kept under specified pathogen-free conditions at the Insti-
tute of Laboratory Animal Sciences, University Hospital Zurich, and all procedures were
approved by the ethical review committee of the cantonal veterinary office of Zurich (license
ZH 104/2013).The animals were health checked the day after and four days after tumor cells
injection. From second week onwards, the mice were controlled three days a week for health
and tumor growth assessment. Animal well-being was monitored by observing behavior, activ-
ity, reactivity, breathing rate, fur appearance, and tumor growth/appearance. Body weight and
tumor size were recorded weekly. Mice were euthanized with CO2, the air displacement being
approx. 20–30% per minute. Criteria for termination used were: tumor diameter of 1.5 cm,
necrotic or open lesions surrarounding the tumor, as well as weight reduction by more than
10%. Tumor excision was performed directly after euthanization and tumors were prepared
for further in vitro analysis (PCR, immunochistochemistry, in vitro cell growth).
Growth of shTLR4 and csh HaCaT in nude mice. HaCaT cells stably transfected with
shTLR4 or control sh were injected into nude mice subcutaneously (4x106 cells/mouse; 6 mice
per group). First measurement of the tumor size was performed 2 weeks after injection and
approximately every 2 weeks further on. The tumor size was measured by caliper, and the
tumor volume was calculated using (height X (width2))/100 formula, where width was the
shorter distance. The differential growth between shTLR4 and control sh tumors was analyzed
statistically for every time point and end day by t-test (p = 0.0002).
Growth of SCC13 TLR4 overexpressing cells in nude mice. SCC13 TLR4 overexpressing
and control cells were injected subcutaneously in nude mice (4x106 cells/mouse) in total of 22
animals divided into 3 groups. First measurement of the tumor size was performed 1 week
after injection and approximately every week further on. The tumor size was measured by cali-
per, and the tumor volume was calculated using the (height X (width2))/100 formula, where
TLR4 and keratinocyte proliferation
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width was the shorter distance. The animals were sacrificed, when the tumors reached either a
volume of 1000mm3 or ulcerated. The differential growth between TLR4 overexpressing and
control SCC13 tumors was analyzed based on the tumor volume for all tumors (p = 0.0192,
Wilcoxon matched-pairs signed rank test). The smallest tumors measured were 100 mm3 at
day 15 post injection (end day).
Immunochistochemical staining of the mice tumors. Hematoxylin staining and control
staining for Ki67 (6¼M7240,1:200 dilution), CD31 (#M0823, 1:40 dilution) and CD68
(#M0814,1:200 dilution) were performed using specific monoclonal mouse anti human anti-
bodies (DAKO). Pre-treatment of the sections was performed using either Proteinase K
(#S3020, DAKO) for CD31 and CD 68 stainings or boiling buffer for Ki67 staining (TRS 9,0,
Epitope Retrieval Solution (10x Concentrate) ph 9,0, #RE 7119, Novocastra)
The staining procedure was performed by Real Detection Alkaline Phospatase system kit
(#K005, DAKO) following the manufacturer‘s protocol.
Results
Expression of TLR4, ATF3 and IRF6 in normal and SCC skin
The total TLR4 expression was analyzed by its immunoreactivity in the epidermis of normal
and SCC-derived patient samples presented as tissue microarrays (TMA) and visualized by
immunohistochemistry (Fig 1A–1C). TLR4 was expressed (red staining) in the perinuclear
(cytoplasm and membrane) region with increasing staining intensity in the highly differenti-
ated keratinocytes.
TLR4 expression was detected in both normal as well as moderately and well differentiated
SCC epidermis (Fig 1D and 1E). The staining intensity of TLR4, IRF6 and ATF3 were arbi-
trarily rated as weak, middle and strong. We observed a correlation in the immunoreactivity
between TLR4 and IRF6 and TLR4 and ATF3 in moderately versus well differentiated SCC
samples (Fig 1F and 1D).
TLR4 expression increases with the differentiation of normal
keratinocytes in vitro
The TLR4 expression was investigated in growing and differentiating normal primary kerati-
nocytes. Differentiating keratinocytes were characterized by higher TLR4, involucrin and filag-
grin expression (Fig 2A and S1 Fig). Similarly, increased TLR4 and involucrin expression was
detected when primary and SCC-derived keratinocytes were driven to differentiate in Cal-
cium-rich conditions in the time interval between 24h and 96h (Fig 2B and S2 Fig).
Knockdown of TLR4 by specific lentiviral short-hairpin RNA (shRNA)
induces keratinocyte proliferation
HaCaT keratinocytes were transfected in duplicates with a specific lentiviral shRNA against
TLR4 and a control shRNA. Induction of keratinocyte proliferation after TLR4 knockdown
was observed by BrDU proliferation assay (Fig 3A and 3B). The difference in cell proliferation
between shTLR4 keratinocytes and control sh keratinocytes was evaluated by t-test on mean
value from three independent experiments (p<0.05; p<0.0001), Fig 3B). The successful
TLR4 knockdown in HaCaT keratinocytes was verified by PCR and immunoblotting (Fig 3C
and 3D and S3 Fig).
TLR4 and keratinocyte proliferation
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Growth of shTLR4 HaCaT keratinocytes in nude mice
HaCaT shTLR4 keratinocytes were injected subcutaneously in nude mice and the growth of
the tumors was investigated at different time points over 3 months. Mice injected with TLR4
knockdown cells developed progressively growing tumors in comparison to mice injected with
control cells (difference at end point, p = 0.0002, t-test, Fig 4A). Only 1 out of 6 control tumors
was still detectable 102 days after injection. This control tumor served as a basis for compari-
son of the TLR4 expression level (Fig 4B). Based on that any further histological or molecular
biological comparison of the control and shTLR4 tumor tissue was not feasible.
Fig 1. Expression of TLR4 in normal human and SCC skin. The expression level of TLR4 was analyzed on formalin-fixed paraffin-embedded skin
samples and tissue microarray samples by immunochistochemistry using specific anti human TLR4 antibody (HTA125, dilution 1:100). The expression
was tested in 225 SCC patient samples (moderately or well differentiated) and in 23 samples from normal skin. (A) Positive staining for TLR4 in normal
epidermis. (B) Positive staining for TLR4 in moderately differentiated SCC. (C) Positive staining for TLR4 in well differentiated SCC. TLR4 positive
keratinocytes show red intensity staining. TLR4 expression is visible in the membrane regions and perinuclear (cytoplasmic) regions and pointed by
arrows. (D) Positive staining for TLR4 found in normal skin and maintained in SCC. (E) Positive staining for TLR4 is found in SCC in different stages of
differentiation (moderately and well differentiated SCC). (F) Positive correlation between TLR4 and IRF6 expression (staining intensity) in moderately
versus well differentiated SCC epidermis. The intensity of staining was analyzed by arbitrary evaluation and presented as arbitrary units respectively as
weak, middle and strong staining. The expression level (intensity) of TLR4, IRF6 and the IRF6/TLR4 correlation were evaluated using t-test and Anova.
P-values below 0.0001 and 0.05 (p<0.05; p<0.0001) were considered as significant.
https://doi.org/10.1371/journal.pone.0185668.g001
TLR4 and keratinocyte proliferation
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SCC13 TLR4 overexpressing cells show a delay in proliferation and
higher migratory activity in vitro
SCC13 tumor cells were stably transfected with TLR4 expressing and control plasmid and
maintained in culture under selection conditions (Blasticidine, 10μg/ml). The transfected
TLR4-GFP cells showed differential intensity of the GFP signal. SCC13 with high TLR4-GFP
signal were separated from the GFP-negative cells by FACS sorting. The sorted cells contained
three populations of GFP positive cells and were distributed into three fractions. The third
fraction (green peak) with highest GFP signal was used further in the study (Fig 5A and S4
Fig).
TLR4 overexpressing cells showed lower proliferation versus control as detected by BrdU
proliferation assay (Fig 5B). Using conventional scratch assay (blocking proliferation by mito-
mycin C) we detected increased migration of TLR4 overexpressing SCC13 cells in comparison
to control cells (Fig 5B).
Growth of SCC13 TLR4 overexpressing cells in vivo
SCC13-TLR4 and control cells were injected subcutaneously into nude mice. The tumor
growth was analyzed based on tumor volume at different time points starting at 1 week after
injection with following 10 and 15 days after injection (S5 Fig). SCC13-TLR4 tumors showed
lower growth in comparison to control tumors: mean tumor volume: 350 mm3 (control) and
250 mm3 (TLR4 overexpressing tumors); p = 0.0192 Wilcoxon matched-pairs signed rank test,
Fig 2. TLR4 expression increases with the differentiation of normal and SCC keratinocytes in vitro. (A) Primary keratinocytes
were grown in duplicates (n = 2) till full confluency at 96h and the expression of TLR4 and keratinocyte differentiation markers (involucrin
and filaggrin) was compared that of low passage (growing) keratinocytes by western blot using specific antibodies. The results were
reproducible in two independent experiments. (B) Primary and SCC-derived keratinocytes were grown in duplicates (n = 2) in the
presence of Ca2+ for different time intervals: 24h, 48h and 96 h. The group “no calcium” was used as positive control for differentiation at
96 hours, the time point of maximal differentiation induced by cell-cell contact. The expression of TLR4 and involucrin was analyzed by
western blot using specific antibodies. The results were reproducible in two independent experiments.
https://doi.org/10.1371/journal.pone.0185668.g002
TLR4 and keratinocyte proliferation
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Fig 3. Knockdown of TLR4 induces proliferation of HaCaT keratinocytes. (A) Growth of sh control and shTLR4
cells under puromycine selection visualized by light microscopy. (B) Knockdown of TLR4 induces cellular proliferation.
The alteration of the proliferation was analyzed by BrDU proliferation assay. The significance was evaluated by t-test
analysis on duplicates (n = 2) from three independent experiments (p*<0.05; p****<0.0001). As a control cells
transfected with a control sh were used. (C) Expression of TLR4 on transcriptional level after TLR4 knockdown. The
differential TLR4 expression in the control and shTLR4 cells was evaluated by qPCR using specific TLR4 primers. (D)
Expression of TLR4 on protein level after TLR4 knockdown. The differential TLR4 expression was evaluated by
conventional western blot analysis using a monoclonal anti TLR4 antibody (HTA 125).
https://doi.org/10.1371/journal.pone.0185668.g003
TLR4 and keratinocyte proliferation
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two-tailed, Fig 6A). The tumors were still overexpressing TLR4 at end day (15 days post injec-
tion) as detected by PCR (Fig 6B). The expression of keratinocyte differentiation markers was
analyzed by qPCR. We detected a variable expression profile of involucrin, filaggrin and K1
within the tumors.
Fig 4. Growth of shTLR4 cells in nude mice. (A) Knockdown of TLR4 induces growth of HaCaT cells in
nude mice (injected 4X103 cells/mouse (mice, n = 6/group); p = 0.0002, t-test). The graphic represents the
tumor growth (tumor volume) at different time intervals post injection. (B) Expression of TLR4 in the control
and sh TLR4 tumors on end day. The differential TLR4 expression was evaluated on transcriptional level by
qPCR using specific anti-human TLR4 primers. The tumor RNA and cDNA synthesis were performed using
TRIzol reagent and RT respectively.
https://doi.org/10.1371/journal.pone.0185668.g004
TLR4 and keratinocyte proliferation
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Fig 5. Overexpression of TLR4 in SCC13 tumor keratinocytes. (A) Visualization of SCC13-TLR4-GFP cells by fluorescent microscopy. SCC13
cells were stably transfected with pUNO-TLR4-GFP and control pUNO-mcs-expressing vectors. TLR4-GFP positive cells revealed nice green
fluorescent staining in contrast to control cells. (B) SCC13-TLR4 cells show lower proliferation and higher migratory activity. The proliferation and
migration of TLR overexpressing cells were investigated by BrDU proliferation assay and scratch assay and compared to cells expressing control
vector only. The alterations in proliferation and migration were statistically significant (n = 4, two independent experiments, p*** = 0.0006,
p****<0.0001, t-test).
https://doi.org/10.1371/journal.pone.0185668.g005
Fig 6. Delayed growth of SCC13-TLR4 overexpressing tumors. (A) Delayed growth of SCC13-TLR4 tumors in nude mice. The graph
represents the tumor volume of the TLR4 and control tumors at day 15 after injection (end day, n = 22; p = 0.0192, Wilcoxon matched-pairs
signed rank test). (B) Expression of TLR4 in SCC13-TLR4 and SCC13-pUNO control tumors at end day. The expression level of TLR4 in
control and TLR4+ tumors was analyzed by qPCR using specific anti human TLR4 primers. The TLR4 overexpressing tumors (n = 22)
retained high levels of TLR4 expression. The graph represents an example of TLR4 expression in animal group 1st (n = 5).
https://doi.org/10.1371/journal.pone.0185668.g006
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The tumor architecture of the excised tumors was analyzed by Hematoxilyn staining and
showed a typical SCC tumor formation, with surrounding tumor infiltrate (Fig 7A). TLR4
overexpressing tumors showed also a lower expression of ki67 proliferation marker in compar-
ison to control tumors (Fig 7B). Ki67 is a proliferation marker routinely used in pathology to
measure the proliferative activity of cells (higher intensity staining correlating with higher pro-
liferation) and little used in routine pathology for SCC. Rather, the measure of differentiation
is a typical distinguishing feature and was thus chosen for grading of SCC in our tissue micro-
arrays. In our mouse models, lacking the standard architecture of human tumors and thus
without a proper measure for differentiation, we used Ki67 expression for detecting differential
proliferation in SCC13-TLR4 overexpressing versus SCC13 control tumors.
The differences in the Ki67 expression level between TLR4 overexpressing tumors and con-
trol tumors were presented as [%] positive cells in the tumor area Ki67 positive cells were
counted out of all cells in the whole section of TLR4 overexpressing and control tumors.
Fig 7. Immunochistochemical analysis of the SCC13 tumors. (A) Hematoxilyn staining (HE) for determining the tumor architecture. The tumor
region and the tumor surrounding tissue (immune infiltrate) are marked with black and red arrows respectively. The staining was performed in all tumors
and using the standard procedure for HE staining. (B) Staining for ki67 proliferation marker in all SCC13-TLR4 and control tumors. The cells expressing
ki67 showed a positive red staining and are pointed with arrows. The intensity of the staining varies depending on the ki67 expression level. (C)
Percentage of Ki67 positive cells in SCC13-TLR4 tumors versus control tumors. The differences in the expression level based on the
immunochistochemical staining were quantified as [%] positive cell/area stained tissue (p = 0.0116, t-test, n = 12 sample group).
https://doi.org/10.1371/journal.pone.0185668.g007
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Afterwards a percentage of the number of such positive cells based on the total number of cells
was calculated (Fig 7C).
The staining intensity of Ki67 was evaluated using t-test. P-values below 0.05 (p<0.05) were
considered as significant.
The tumor tissues were further investigated for detection of tumor vascularization, immune
infiltration and metastasis in internal organs using immunohistochemistry. We did not detect
any significant difference in the staining intensity of CD31 and CD68 in the tumor infiltrate
between the TLR4 tumors and control tumors (Fig 8A). We did not detect also any tumor cells
in the surrounding lymph nodes, lung or liver of the mice on end day (Fig 8B).
Extended time points for investigation of metastatic potential were not possible, as fast
tumor growth combined with tumor ulceration required us to sacrifice animals as by the law.
Functional relevance of TLR4 in SCC13 TLR4 expressing cells
Expression of pERK, pJNK and ATF3 in TLR4 overexpressing SCC13 cells. The func-
tional relevance of TLR4 was tested by LPS stimulation. We analyzed the phosphorylation of
ERK and JNK at different time points after LPS stimulation (Fig 9A and S6 Fig). We detected
increased basal phosphorylation of JNK in unstimulated TLR4 overexpressing SCC13 cells in
comparison to control cells. The increased phosphorylation was still detectable 15 min after
LPS stimulation and decreased further in the course of LPS treatment. Similarly, increased
phosphorylation of ERK in TLR4 overexpressing cells was observed in LPS-free conditions,
which in contrast to JNK was inducible in presence of LPS. LPS also induced the expression of
ATF3 in TLR4+ cells 15 minutes after treatment. SCC13 TLR4 cells showed lower, but LPS
inducible IL-6 secretion in comparison to untreated cells (Fig 9B). We did not detect any alter-
ation of pIRAK1 or MyD88 expression.
Overexpression of TLR4 leads to differential gene expression in SCC13
cells
The gene expression profile between SCC13-TLR4 and control SCC13-pUNO cells in presence
or absence of LPS was investigated by cDNA microarray analysis. Upregulated and downregu-
lated genes of interest were selected based on their statistically significant alteration in the
expression level and according to their relevance in cell proliferation and migration in skin
malignancy (Fig 10A). Within the upregulated genes were ATF3, CDH13 and CXCL-1,-12
and within the downregulated genes were IL-6, IL6R and TFPI. ATF3 upregulation in unsti-
mulated SCC cells was confirmed on a protein level and its expression showed positive correla-
tion to the TLR4 expression in patient SCC samples (Figs 9A and 10 and S7 Fig). The
downregulation of IL-6R correlated with the downregulation of the secreted IL6 in LPS free
conditions as revealed by ELISA (Fig 9B).
The gene expression profile of LPS treated SCC13-TLR4 cells did not reveal significant
alterations in comparison to the LPS untreated cells.
Discussion
In this study we investigate the role of TLR4 as a regulator of keratinocyte proliferation. We
first analyzed the total expression of TLR4 in normal and SCC skin in TMA sections, where we
detected immunoreactivity for TLR4 for all samples (Fig 1). The results shown in Fig 1E con-
firmed that TLR4 is expressed in both moderately and well differentiated SCC.
Interestingly, we observed a positive correlation between the expression of TLR4 and IRF6
in moderately versus well differentiated SCC keratinocytes (Fig 1F). This suggests that TLR4
TLR4 and keratinocyte proliferation
PLOS ONE | https://doi.org/10.1371/journal.pone.0185668 October 5, 2017 13 / 23
expression increases with the differentiation of normal and SCC epidermis, as IRF6 is a tran-
scription factor involved in epithelial differentiation [9, 26].
Such a correlation between the level of TLR4 and keratinocyte differentiation was also
observed in an in vitro study, where the differentiation of normal and SCC keratinocytes was
driven by known differentiation agents, such as Ca2+ (Fig 2B). A relation between passage
growth and TLR4 expression has been previously observed, however in HaCaT cell line [27].
Other publications used other antibodies which we did not compare side to side in our
experiments. We do show, however, as other authors found for several skin disease conditions
that in our tumors TLR4 immunoreactivity increases towards the lumen, i.e. upper parts of the
epidermis [28]. Our samples of normal epidermis stained are from sun-damaged areas of the
skin, thus not easily comparable to the ones used by other authors, but apt in our study of
human SCC where we want to capture the difference between benign, sun-damaged skin and
malignant skin cancer, SCC.
A direct functional relation between TLR4 and keratinocyte proliferation and differentia-
tion has not been investigated by now. The basis of our study is the direct relationship between
TLR4 expression and keratinocyte growth in the absence of external stimuli and dependent on
the TLR4 levels and intracellular mechanisms controlling the keratinocyte lifespan only. In
Fig 8. Immunochistochemical analysis of the SCC13 tumor vascularization, immune infiltration and metastasis. (A) Staining for CD31 and
CD68 expression. The red positive signal corresponds to the expression of CD31 in the endothelial cells and the blood vessels respectively (black
arrows). CD68 positive cells (macrophages) are stained in red and are present in the surrounding tumor infiltrate and the peripheral tumor area (black
arrows). (B) Hematoxilyn staining for determining the organ-specific cellular architecture. The stainings were performed using specific antibodies
against human Ki67, CD31 and CD68. All images are presented at low (5X) and highest (20X) magnification.
https://doi.org/10.1371/journal.pone.0185668.g008
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Fig 9. Functional relevance of TLR4 in SCC13-TLR4 cells. (A) Altered expression profile of pERK, pJNK
and ATF3 in SCC13-TLR4 cells. The functionality of TLR4 was investigated upon LPS treatment for different
time points and the differential expression/ phosphorylation profile was analyzed by western blot using
specific antibodies. The phosphorylation of ERK and JNK was induced at 15–30 min after LPS treatment in
both of the cell lines. SCC13-TLR4 cells showed increased phosphorylation of ERK and JNK in LPS-free
conditions in comparison to SCC13-pUNO cells. SCC13-TLR4 cells show an increased ATF3 expression in
LPS-free conditions in comparison to SCC13-pUNO control cells. The ATF3 expression was induced at 15
min after LPS stimulation in both of the cell lines. The results represent an example of two independent LPS
treatments. (B) Alteration of IL-6 secretion in SCC13-TLR4 cells. SCC13-TLR4 and control SCC13-pUNO-
cells were seeded in duplicates (n = 2) and induced by LPS at time points 15, 30, 45 and 60 min. Six and 24h
after LPS stimulation cell supernatants were collected and analysed for IL-6 expression using ELISA and
compared to untreated cells. LPS untreated SCC13-TLR4 cells show lower levels of IL6 in the cellular
supernatant in comparison to control SCC13-TLR4 cells.
https://doi.org/10.1371/journal.pone.0185668.g009
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relation to that we present that knockdown of TLR4 induces proliferation of keratinocytes in
vitro and in vivo (Figs 3 and 4). Hyperproliferation of keratinocytes is observed mostly in
inflammatory skin diseases as psoriasis [29]; [30]. TLR4 is expressed in psoriatic skin [31];
[14], however, a direct regulation of proliferation by TLR4 in the keratinocytes has not been
discussed. Studies in TLR4 deficient mice and in vitro studies revealed involvement of TLR4 in
Fig 10. Altered gene expression in SCC13-TLR4 versus SCC13-pUNO control cells revealed by microarray analysis. Gene expression array:
SCC13-TLR4 and control SCC13-pUNO- cells were seeded in tetraplicates (n = 4) and induced by LPS for 24 hours. The SurePrint G3 Human Gene
Expression 8x60K (Agilent) with 50599 biological features was used to analyze the samples. Differentially expressed genes were selected as
significant if the absolute log-fold change was more than 2 and FDR adjusted p-value was less than 0.05. (A) Clustering of significant probes and GO
Analysis. Red GO categories are overrepresented among the significantly upregulated genes. Blue GO categories are overrepresented among the
significantly downregulated genes. Black GO categories are overrepresented among all signifcantly regulated genes. The genes of interest with
validated expression are presented in the table. (B) Positive correlation between TLR4 and ATF3 expression in moderately versus well differentiated
SCC epidermis. The intensity of staining was analyzed by arbitrary evaluation and presented as arbitrary units respectively as weak, middle and strong
staining. The expression level (intensity) of TLR4, ATF3, and the ATF3/TLR4 correlation were evaluated using t-test and Anova. P-values below
0.0001 and 0.05 (p<0.05; p<0.0001) were considered as significant.
https://doi.org/10.1371/journal.pone.0185668.g010
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skin wound healing [17]; [32]. In contrast to our results the authors describe activation of
TLR4 signaling upon immune stimuli, which induces keratinocyte proliferation. A direct
involvement, however, of TLR4 expressed on keratinocytes as a negative regulator of keratino-
cyte proliferation is not discussed.
Our study suggests that TLR4 is also a regulator of migration, proliferation and growth of
SCC tumors. We show that TLR4 overexpression reduces proliferation and induces migration
of SCC13 cells in vitro and delays growth of SCC13 tumors in vivo (Figs 5 and 6). In addition
to that, our results revealed that the tumor delay of TLR4 overexpressing tumors correlated
with the lower expression of ki67 proliferation marker (Fig 7). Different phenotypes of cancer
cells either accentuating migration or proliferation have been described previously [33]. We
believe that our manipulation of TLR4 in SCC13 had a greater effect on migration than prolif-
eration. However, the effect on proliferation and migration cannot be compared directly as for
the migration assay the cells were maintained under starving conditions and proliferation was
blocked additionally by mitomycin C.
SCC13 cells are a suitable model for investigation of TLR4 dependent proliferation, how-
ever, differentiation of SCC13 cells based on TLR4 expression proved difficult to ascertain due
to an insufficient Notch signaling pathway in these cells [34]; [35].
Generally, SCC13 are known also for their high metastatic potential [36]; [37]. We, how-
ever, did not detect any tumor cells in lymph nodes or other organs of the treated animals (Fig
8B), possibly due to early termination of the experiments based on ulceration of the primary
tumor, demanding animals to be sacrificed. The nude mice used in this study are suitable
model for the investigation of skin tumor development. However, these mice are largely
immunodeficient as they lack functional T and B cells. Therefore, additional investigations
concerning immune response against the tumor, for example, were not feasible. Our findings
focused on keratinocyte behavior in relation to TLR4, not an immunological interplay with
the microenvironment.
Human patient material and in vivo models in rodents have been studied for the involve-
ment of TLR4 in tumor progression, although the focus of these projects was mainly on the
involvement of the innate immune system [38]; [19]; [21]; [39, 40]; [16]. Studies in TLR4-defi-
cient mice revealed that TLR4 has a supportive role in the development of chemically induced
skin cancer through immune response [21]; [19]. While these mice are globally deficient for
TLR4 with a big impact on innate immunity to be expected, tumor cell cultures originating
directly from the DMBA-induced skin tumors in TLR4-deficient mice, however, show an
increased proliferative capacity in comparison to tumors of control mice in the absence of
immune cells. This supports our data concerning TLR4 expression and keratinocytes prolifera-
tion and tumor growth.
We observed specific phosphorylation changes of pERK and pJNK dependent on the TLR4
levels in tumor keratinocytes (Fig 9A).
The phosphorylation pattern of ERK and JNK after LPS stimulation in TLR4 overexpres-
sing cells confirms the functionality of TLR4 in our model. Based on our results we suggest a
relationship of ERK and JNK pathways and TLR4 overexpression, possibly contributing to the
balance of proliferation and differentiation. This balance might be additionally maintained by
the expression of IL6. Interestingly, SCC13-TLR4 cells showed lower IL6 expression than con-
trol cells, but still inducible by LPS (Fig 9B). These results point to both TLR4–related IL6
expression and confirmation of TLR4 functionality in our model. IL6 is known to be involved
in the metastatic and invasion properties of melanoma, SCC of the skin and Head and Neck
SCC [41]; [42].
Furthermore, using gene expression analysis in SCC13-TLR4 cells we identified and vali-
dated genes reported to be involved in proliferation and migration of malignant cells
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(Fig 10A). Interestingly, among the upregulated genes was ATF3, which expression correlated
with the TLR4 expression in SCC13 TLR4 cells (Fig 9A) and in the SCC TMA (Fig 10B). ATF3
is reported as transcription factor involved in the pathogenesis of epithelial cancer and psoria-
sis [36]; [23]; [24, 43]. In relation to that, ATF3 is known to be a negative regulator of IL6 [44]
[45]; [46]. This correlates with our results showing that TLR4 overexpressing cells have
increased ATF3 expression and decreased IL-6 secretion. Based on that we suggest that ATF3
together with TLR4 and IL6 might be involved as a negative regulator of keratinocyte prolifera-
tion. In contrast to our results, some reports show a protective role of ATF3 in SCC, however
in their relation to immunosuppressive agents [23]; [24]
Another upregulated gene was CDH13 (Cadherin H), known to participate as a modulator
of proliferation and migration in melanoma, SCC and BCC [47]; [48, 49] as well as CXCL pro-
teins, involved in the control of epithelial-mesenchymal interaction in normal or malignant
epithelial cells [50]. Together with IL-6, among the downregulated genes was TFPI. TFPI is
known to be involved in the formation of matrix-rich vascular-like networks in melanoma
[51, 52]; [53] and is used as a diagnostic marker for SCC [54].
Since these individual genes have all been described in cancer models and tissue, we reason
their dependence on TLR4 expression as shown in our study supportive for the suggested role
of TLR4 in tumor growth.
Altogether we assume that TLR4 impacts keratinocyte biology as a regulator of proliferation
in normal and tumor keratinocytes and also in the migration of tumor cells. Thus TLR4 as
negative regulator of keratinocyte proliferation may associate with the progression of SCC of
the skin. A better understanding of the regulatory role for TLR4 will be the basis for a later use
in a therapeutic setting to impair keratinocyte proliferation such as in squamous cell carci-
noma of the skin and to induce keratinocyte proliferation such as in wound healing.
Supporting information
S1 Fig. Quantitative estimation of the expression of TLR4, Involucrin and filaggrin in nor-
mal primary keratinocytes. The quantitative estimation was based on calculating the spot
density of the bands for TLR4, involucrin and filaggrin and compared to the spot intensity of
the actin bands. This was performed by LI-COR ODYSSEY1 Fc Dual-Mode Imaging System
and Image Studio Lite Program. All quantitative estimations represent the spot density on the
entire western blot, which is representative for two independent experiments with reproduc-
ible result. (A) Quantitative estimation of the TLR4, involucrin and filaggrin expression in
growing versus confluent primary normal keratinocytes (PK). The expression of TLR4, involu-
crin and filaggrin is presented as a ratio between the spot density (arbitrary units) of the bands
for these proteins and the spot density of the corresponding actin bands. The differential
expression of those proteins in confluent keratinocytes was compared to their expression level
in growing cells and presented as “% of control” (“control” = growing cells). (B) Quantitative
estimation of TLR4 and involucrin expression in primary normal keratinocytes (PK) before
and after treatment with Ca2+. TLR4 expression was analyzed in low Ca conditions (0h and
96h) and at 24h, 48h and 96 hours after Ca2+ treatment (1.5mM CaCl2). The quantified expres-
sion of TLR4 and involucrin is presented as a ratio between the spot density (arbitrary units)
of the TLR4 and involucrin bands and the spot density of the corresponding actin bands. The
differential expression of TLR4 for every time point is compared to its expression level in
untreated cells and presented as “% of control”.
(TIFF)
S2 Fig. Quantitative estimation of TLR4 and involucrin expression in primary SCC kerati-
nocytes before and after treatment with Ca2+. TLR4 expression was analyzed in low Ca
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conditions (0h and 96h) and at 24h, 48h and 96 hours after Ca2+ treatment (1.5mM CaCl2).
The quantified expression of TLR4 and involucrin is presented as a ratio between the spot den-
sity (arbitrary units) of the TLR4 and involucrin bands and the spot density of the correspond-
ing actin bands. The differential expression of TLR4 for every time point is compared to its
expression level in untreated cells and presented as “% of control”.
(TIFF)
S3 Fig. Densitometrical quantification of TLR4 level in shTLR4 and control protein sam-
ples. The quantitative estimation of the differential expression was based on calculating the
spot density of the bands corresponding to sh control and shTLR4 bands. This was performed
by Image J software programm.
(TIFF)
S4 Fig. SCC13 cells express TLR4-GFP. SCC13 stably transfected with TLR4-GFP show dif-
ferent populations of cells according to their GFP signal. SCC13 with high TLR4-GFP signal
were separated from the negative TLR4-GFP population by FACS sorting, using FACSAria III.
The FACS diagrams show the cellular distribution according to the GFP signal before and
after sorting. The sorted cells contained three populations of cells according to their GFP signal
and were distributed into three fractions. The third fraction (green peak) with highest GFP sig-
nal was used further in the study.
(TIFF)
S5 Fig. Delayed growth of SCC13-TLR4 overexpressing tumors in comparison to control
tumors during the time course. SCC13 TLR4 overexpressing and control cells were injected
subcutaneously in nude mice (4x106 cells/mouse). Tumor volume was measured preliminary
at 1 week, 10 days and 15 days after injection. The graph represents preliminary tumor growth
in sample groups 1st and 2nd pooled together, n-13).
(TIFF)
S6 Fig. Quantitative estimation of of pERK and pJNK before and after LPS treatment.
SCC13 TLR4 overexpressing and SCC13pUNO control cells were treated with 10μg/ml ultra-
pure LPS in a time course of 15min, 35min, 45 min and 60 min. The expression of pERK /ERK
and pJNK/JNK was analyzed by western blotting. All quantitative estimations represent the
spot density on the entire western blot, which is representative for two independent experi-
ments with reproducible result. (A) Quantitative estimation of pERK before and after LPS
treatment. The quantified expression of pERK and ERK is presented as a ratio between the
spot density (arbitrary units) of pERK bands and the spot density of the corresponding ERK
bands. The differential expression of pERK for every time point is compared to its expression
level in untreated cells and presented as “% of control”. (B) Quantitative estimation of pJNK
before and after LPS treatment. The quantified expression of pJNK and JNK is presented as a
ratio between the spot density (arbitrary units) of pJNK bands and the spot density of the cor-
responding JNK bands. The differential expression of pJNK for every time point is compared
to its expression level in untreated cells and presented as “% of control”.
(TIFF)
S7 Fig. Quantitative estimation of ATF3 before and after LPS treatment. The quantified
expression of ATF3 is presented as a ratio between the spot density (arbitrary units) of the
ATF3 bands and the spot density of the corresponding actin bands. The differential expression
of ATF3 for every time point is compared to its expression level in untreated cells and pre-
sented as “% of control”.
(TIFF)
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S8 Fig. Control immunochistochemical staining. (A) Positive control staining for TLR4
expression in human placenta. The TLR4 detection antibody (HTA 125) was used in a dilution
1:100. The images are presented at magnifications 5X and 20X. The positive red staining repre-
sents the TLR4 expression. (B) Negative control staining. The negative control staining was
performed on human placenta and in the absence of the TLR4 antibody. (C) Differential TLR4
expression in normal epidermis. The basal keratinocyte layer is characterized by weak red
intensity staining for TLR4 (red arrows). Upper and high-differentiated layers show stronger
red intensity staining for TLR4 (black arrows).
(TIFF)
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